ALX Oncology Holdings Inc. (ALXO)
| Previous close | 15.50 |
| Open | 15.59 |
| Bid | 15.55 x 100 |
| Ask | 15.75 x 100 |
| Day's range | 15.24 - 15.88 |
| 52-week range | 3.94 - 17.42 |
| Volume | |
| Avg. volume | 469,130 |
| Market cap | 793.084M |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.74 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.15 |
GlobeNewswireALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024. Session titles and information for the two abstracts are listed below and are now
ZacksRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ZacksALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
